Applicability of pharmacogenomic testing in the treatment of major depressive disorder

被引：0
|
作者：
Ramos, S. [1 ]
Sousa, D. [1 ]
Mendes, J. [1 ]
机构：
[1] EPE, Unidade Local Saude Guarda, Psychiat, Guarda, Portugal
来源：
EUROPEAN PSYCHIATRY | 2020年 / 63卷
关键词：
major depressive disorder; Pharmacogenomics;
D O I：
暂无
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
EPP0929
引用
收藏
页码：S655 / S656
页数：2
相关论文
共 50 条
  • [1] Pharmacogenomic Testing to Guide Treatment of Major Depressive Disorder: A Systematic Review
    Farah Khorassani
    Mandy Jermain
    Christine Cadiz
    [J]. Current Treatment Options in Psychiatry, 2024, 11 (2) : 123 - 140
  • [2] Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting
    Hall-Flavin, Daniel K.
    Winner, Joel G.
    Allen, Josiah D.
    Carhart, Joseph M.
    Proctor, Brian
    Snyder, Karen A.
    Drews, Maureen S.
    Eisterhold, Linda L.
    Geske, Jennifer
    Mrazek, David A.
    [J]. PHARMACOGENETICS AND GENOMICS, 2013, 23 (10): : 535 - 548
  • [3] Pharmacogenomic predictors of citalopram treatment outcome in major depressive disorder
    Mamdani, Firoza
    Berlim, Marcelo T.
    Beaulieu, Marie-Martine
    Turecki, Gustavo
    [J]. WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2014, 15 (02): : 135 - 144
  • [4] Cost-Effectiveness of Combinatorial Pharmacogenomic Testing for Treatment-Resistant Major Depressive Disorder Patients
    Hornberger, John
    Li, Qianyi
    Quinn, Bruce
    [J]. AMERICAN JOURNAL OF MANAGED CARE, 2015, 21 (06): : E357 - +
  • [5] The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder: A meta-analysis
    Rosenblat, Joshua D.
    Lee, Yena
    McIntyre, Roger S.
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2018, 241 : 484 - 491
  • [6] SUBPHENOTYPES IN MAJOR DEPRESSIVE DISORDER TO BETTER CHARACTERIZE PHARMACOGENOMIC ANTIDEPRESSANT TREATMENT RESPONSE
    Ahmed, A. T.
    Frye, M. A.
    Rush, A.
    Bobo, W. V.
    Biernacka, J.
    Flavin, D. Hall
    Jenkins, G. D.
    Batzle, A.
    Skime, M. K.
    Wang, L.
    Craighead, W.
    Mayberg, H. S.
    Weinshilboum, R. M.
    Kaddurah-Daouk, R. F.
    Dunlop, B. W.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S19 - S20
  • [7] Treatment for major depressive disorder
    Zhang, X.
    [J]. PSYCHOTHERAPY AND PSYCHOSOMATICS, 2015, 84 : 81 - 81
  • [8] Potential Differences in Pharmacogenomic Associations with Improvement in Anxiety During Duloxetine Treatment of Generalized Anxiety Disorder and Major Depressive Disorder
    Perlis, Roy H.
    Fijal, Bonnie
    Dharia, Sweta
    Heinloth, Alexandra N.
    Houston, John P.
    [J]. BIOLOGICAL PSYCHIATRY, 2010, 67 (09) : 214S - 214S
  • [9] A Combinatorial Pharmacogenomic Algorithm is Predictive of Sertraline Metabolism in Patients With Major Depressive Disorder
    Parikh, Sagar
    Law, Rebecca
    Hain, Daniel
    Rothschild, Anthony
    Thase, Michael
    Dunlop, Boadie
    DeBattista, Charles
    Forester, Brent
    Shelton, Richard
    Macaluso, Matthew
    Cogan, Elizabeth
    Brown, Krystal
    Lewis, David
    Jablonski, Michael
    Greden, John
    [J]. NEUROPSYCHOPHARMACOLOGY, 2021, 46 (SUPPL 1) : 273 - 274
  • [10] Combinatorial pharmacogenomic algorithm is predictive of sertraline metabolism in patients with major depressive disorder
    Parikh, Sagar V.
    Law, Rebecca A.
    Hain, Daniel T.
    Rothschild, Anthony J.
    Thase, Michael E.
    Dunlop, Boadie W.
    DeBattista, Charles
    Forester, Brent P.
    Shelton, Richard C.
    Macaluso, Matthew
    Cogan, Elizabeth S.
    Brown, Krystal
    Lewis, David J.
    Jablonski, Michael R.
    Greden, John F.
    [J]. PSYCHIATRY RESEARCH, 2022, 308
12345